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Preoperative radiotherapy (PRT) in resectable rectal cancer improves local control but increases probability of faecal incontinence
and sexual dysfunction. Consensus was reached in 2001 in the Netherlands on a guideline advising PRT to new patients. Purpose was
to assess at what benefit oncologists and rectal cancer patients prefer PRT followed by surgery to surgery alone, and how oncologists
and patients value various treatment outcomes. Sixty-six disease-free patients and 60 oncologists (surgical, radiation, medical) were
interviewed. Minimally desired benefit from PRT (local control) was assessed using the Treatment Tradeoff Method. Importance of
survival, local control, faecal incontinence, and sexual dysfunction in determining treatment outcome preferences was assessed using
Adaptive Conjoint Analysis. The range of required benefit from PRT varied widely within participant groups. Seventeen percent of
patients would choose PRT at a 0% benefit; 11% would not choose PRT for the maximum benefit of 11%. Mean minimally desired
benefit excluding these two groups was 4%. For oncologists, the required benefit was 5%. Also, how strongly participants valued
treatment outcomes varied widely within groups. Of the four outcomes, participants considered incontinence most often as most
important. Relative treatment outcome importance differed between specialties. Patients considered sexual functioning more
important than oncologists. Large differences in treatment preferences exist between individual patients and oncologists. Oncologists
should adequately inform their patients about the risks and benefits of PRT, and elicit patient preferences regarding treatment
outcomes.
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Rectal cancer affects approximately 2500 new patients yearly in the
Netherlands (Comprehensive Cancer Centers, the Netherlands,
http://www.ikcnet.nl/IKZ/index.php?id¼1646&nav_id¼160&regio_
id¼124, accessed on 14 December 2006), and 5-year survival is
around 65% (Peeters et al, 2006). A Dutch multimember trial (total
mesorectal excision (TME) trial) showed neoadjuvant radiotherapy
(5 5Gy) followed by TME surgery to improve local control
compared to TME surgery alone in resectable rectal cancer patients
at 2-year follow-up, with no survival benefit (Kapiteijn et al, 2001).
A Swedish population-based study showed similar results (Dahlberg
et al, 1998). As local recurrences result in painful and severe
disabling symptoms that are difficult to treat, a national guideline
was agreed upon in 2001 based on these results, advising
preoperative radiotherapy (PRT) for all resectable rectal cancer
patients. Five-year follow-up trial data confirmed a reduced
recurrence rate (from 11 to 6%), still with no survival benefit
(Peeters et al, 2006). Irradiated patients reported higher rates of
faecal incontinence compared to non-irradiated patients at 2- and
5-year follow-up (Marijnen et al, 2005; Peeters et al, 2005). The
Swedish Rectal Cancer Trial showed comparable results at a mean
of 6 years follow-up (Dahlberg et al, 1998). Moreover, irradiated
patients showed higher rates of sexual dysfunction at 2-year
follow-up (Marijnen et al, 2005).
Treating all eligible patients with PRT implies that many will
be treated unnecessarily. It is presently questionable how strongly
oncologists believe the benefit from PRT on local control to
outweigh the risks. At the time of our study, PRT was the
standard treatment in the Netherlands, but it was expected that
the guideline might undergo changes, due to the publication of the
above studies of Marijnen et al (2005) and Peeters et al (2005).
Additionally, patients’ views on the underlying risk/benefit
tradeoff have never been assessed. Our study was undertaken to
assess (a) at what benefit patients and oncologists prefer PRT
followed by surgery to surgery alone, (b) how patients
and oncologists value various treatment outcomes, and (c) whether
characteristics of patients and oncologists affect preferences.
The method used to value treatment outcomes is novel.
This study may therefore serve as a model for similar
tradeoffs in other cancer treatment decisions, as tradeoffs
between tumour control and quality of life are abundant in
oncology.
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sMATERIALS AND METHODS
Study population
To obtain as much variance in preferences as possible, we stratified
sampling by PRT, type of surgery (permanent stoma or not), and
incontinence/sexual dysfunction (if the tumour is close to the anal
verge, rectal cancer surgery results in a permanent stoma; patients
without a stoma face the risk of faecal incontinence). We aimed to
include 60 disease-free rectal cancer patients, half of whom had
been treated with surgery alone and half with PRT followed by
surgery. In both groups, half should have reported sexual
dysfunction at 2-year follow-up, and two-third should be without
a permanent stoma. Of them, half should have reported faecal
incontinence at 5-year follow-up. We randomly selected these
patients from those participants of the TME trial who had agreed
at 5-year follow-up to being approached for further research,
and who were below age 90. Ninety-four eligible patients were
approached. Four patients could not be reached. Nine had (had)
other types of cancer or recurrent disease and were excluded. Of
the remaining 81 patients, 70 (86%) agreed to participate. Reasons
for refusal were the psychological burden (N¼8), physical burden
(N¼1), time investment (N¼1), or unknown (N¼1).
We further aimed to include 60 oncologists. Seventy eligible
oncologists were approached and 61 (87%) agreed to participate
(25 surgical, 26 radiation, 10 medical). Reasons for refusal were
time constraints (N¼3), considering participation not meaningful
(N¼1 medical oncologist), being retired (N¼1), unknown
(N¼1), or because oncologists could not be reached despite
repeated attempts (N¼3). Participating oncologists were specia-
lised in gastroenterology and worked in academic and non-
academic institutions. Participants were informed about the study
by letter, and then asked for participation by telephone.
Procedure
Individual face-to-face interviews were held at their home
(patients) or institution (oncologists). At the beginning of the
interview, patients were asked for informed consent. The
interviewers were trained and adhered to a strict interview script.
Furthermore, the Adaptive Conjoint Analysis (ACA) was fully
computerised. For these reasons, possibility of an interviewer
effect was minimal. The Medical Ethical Board of the Leiden
University Medical Center approved the study. Socio-demo-
graphic, medical history (patients), and work-related (oncologists)
details were assessed by self-report questionnaire, a week before
the interview.
Measures
Minimally desired absolute benefit (local control) from PRT was
assessed using the Treatment Tradeoff Method (TTM) (Llewellyn-
Thomas, 1997). The TTM presented sequentially a short descrip-
tion of the two treatments and the respective probabilities of side
effects as had been established at 2-year (sexual dysfunction;
Marijnen et al, 2005) and 5-year (incontinence; Peeters et al, 2005)
follow-up. Figure 1 depicts the male version. In the female version,
numbers for sexually active patients were 15 (surgery) and 22
(PRTþsurgery) out of 100 for dysfunction (Sexual dysfunction
includes sexual inactivity. The overall numbers for dysfunction in
female patients were 52% in the non-irradiated group and 57%
in the irradiated group. We chose to present numbers for sexually
active patients only, as too many respondents may otherwise
disregard the difference between the treatment groups on this
aspect). The interviewer explicitly stated that 5-year survival was
the same following either treatment. Next, the probability of 5-year
local control after surgery alone was presented (Peeters et al, 2005,
2007). The probability of 5-year local control with PRT was then
varied and participants were asked each time which treatment they
preferred: first (patients only) local control in 89 out of 100
patients (i.e. no benefit), then local control in 100 out of
100 patients (i.e. maximum benefit), and local control in 95 out
of 100 patients. Participants’ minimally desired benefit was
searched by systematically bracketing the numbers further within
the range of 89 out of 100 to 100 out of 100.
Next, relative importance of treatment outcomes was assessed
using a computer-administered ACA task. This method has not
been used in oncology as of yet, but has been applied in studies
involving rheumatology (Fraenkel et al, 2001, 2004a,b, 2006), HIV
(Beusterien et al, 2005), and major abdominal surgery patients
(Gan et al, 2004). Elsewhere we have described methodological
aspects of this new method in an oncology setting (Pieterse et al,
2007). Preferences for various probabilities of 5-year survival,
5-year local control, faecal incontinence, and sexual dysfunction
were elicited by asking participants to tradeoff combinations of
these. Survival was included to make results more generalisable, as
adjuvant treatment may improve survival after longer follow-up
and in other cases. It was explicitly stated that survival and local
control should be viewed as independent outcomes. Ranges of
probability estimates included those that were established at 2-year
(sexual dysfunction; Marijnen et al, 2005) and 5-year (survival,
local control, incontinence; Peeters et al, 2005, 2007) follow-up
(Table 1). Treatment modality was not specified. Separate versions
of the ACA questionnaire were built for male and female patients.
The ACA questionnaire first asked participants to rate how
important they considered the difference between the best and
worst probability of each outcome (all else being equal) on a
four-point scale (Fraenkel et al, 2001, 2004a,b) (Figure 2). Next,
participants were asked to rate 14 pairs of combinations of
outcomes, where each combination consisted of two or three
outcomes. Participants were asked to indicate their preference and
strength of preference on a seven-point scale (Beusterien et al,
2005) (Figure 2). ACA customises the task to individual
participants by presenting combinations representing tradeoffs
that participants consider as increasingly relevant, based on their
previous replies. The ACA analysing program (version 5.2.2,
Sawtooth Software, Sequim, WA, USA) estimates how highly
participants value each outcome probability and computes
participants’ relative importance score for each outcome, ex-
pressed as a percentage (importance scores add up to 100%) (ACA
5.0 Technical Paper, 2005). This score indicates the extent to which
one outcome explains a participant’s preference in choosing
between outcome states, relative to the other outcomes. Due to
the computation algorithm, the importance score for a specific
outcome tends to be positively related to its range of probability.
Importance scores should therefore not be viewed as absolute
preferences. In an earlier analysis of the data, we showed that mean
group importance could reliably be assessed over time (Pieterse
et al, 2007).
In both TTM and ACA, quantitative frequency formats were
used to facilitate understanding (Gigerenzer, 1996) and patients
were asked to imagine that they had recently been diagnosed with
cancer. Patients answered the gender-matching version of each
task. Oncologists answered the TTM task for both male and female
patients (in randomised order), and answered one randomly
selected version of the ACA task.
Statistical analyses
Descriptive statistics were used to describe participants and their
minimally desired absolute benefit from PRT (TTM). Benefit was
compared for socio-demographic, treatment- (patients), and work-
related (oncologists) characteristics using the Kruskal–Wallis
tests, independent t-tests, or Pearson’s correlations. Treatment
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spreference was said to be surgery alone if participants required a
benefit exceeding the absolute 5% increase in probability of local
control (Peeters et al, 2007). Patients’ and oncologists’ preferences
were compared using a w
2-test. Regarding the ACA, we assessed
whether participants’ valuation of outcome probabilities was in
agreement with probabilities from best to worst, within each of the
four outcomes. Participants who valued the lowest probability of a
good outcome highest were excluded from further analyses.
Descriptive statistics were used to describe participants’ relative
importance, and these were compared using ANOVA and
independent t-tests. Post hoc comparisons were analysed using
the Bonferroni test. All significance testing was performed two-
tailed at a¼0.05.
RESULTS
Participants
Table 2 lists demographic, treatment- (patients), and work-related
(oncologists) details. Of the 70 patients, 66 (94%; 45 male, 21
female) completed the TTM- and ACA tasks. One patient had so
many difficulties in comprehending numbers that he did not
complete the TTM task and was not asked to perform the ACA
task. Others did not perform the ACA task due to a computer
failure (N¼1) or finding the task too difficult (N¼2).
One radiation oncologist completed the questionnaire and
withdrew from the interview because of time constraints. All
Treatment
Surgery
•  You undergo surgery to remove the 
tumour 
•  Both the disease and surgery may
cause physical, psychological
and/or social problems   
Radiation+Surgery 
• You undergo surgery to remove the
tumour 
•  In the week before surgery, you are
irradiated on five consecutive days 
•  Both the disease, surgery and the
irradiation may cause physical,
psychological and/or social problems  
Side effects 
Unintentional
loss of stools  40 out of 100 people 60 out of 100 people
Sexual 
problems 56 out of 100 men 68 out of 100 men
Consequence
No
local recurrence of the 
disease within 5 years  
From time to time, worry and
anxiety about recurrence of the 
disease may be present   
Local recurrence of the 
disease within 5 years  
This results in severe pain
symptoms. A recurrent tumour is
difficult to treat. The prognosis is
now uncertain   
89
11
out of 100 people  
out of 100 people 
?
?
Figure 1 Consecutive information (treatment options, side effects, and consequence) presented with the TTM (male patient).
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ssurgeons as well as 14 out of 25 radiation and 9 out of 10 medical
oncologists were male.
Minimally desired benefit from PRT
Figure 3 shows the cumulative proportion of participants
preferring PRT according to minimum benefit. Seven (11%)
patients would not choose PRT for the maximum benefit of 11%.
Eleven (17%) patients would choose PRT at no benefit. In the other
48 patients, average minimally desired benefit was 4.4% (95% CI
3.6–5.3; range 1–11). Overall, average minimally desired benefit
was not significantly different for male and female patients
(3.3±2.8 vs 4.4±3.8, P¼0.20), and was significantly lower for
irradiated patients (2.6±2.6 vs 5.1±3.3, Po0.001) and those with
a stoma (2.1±2.4 vs 4.5±3.2, P¼0.01).
One medical oncologist would not advise PRT to male patients,
and only for a 7% benefit to female patients. One surgical
oncologist would advise PRT to male patients for 6% benefit, but
Table 1 ACA treatment outcomes and outcome-probabilities (Frequencies out of 100 patients)
Outcome Explanation Outcome probabilities (from best to worst)
Probability of 5-year survival
(all patients)
This is the probability that the patient is still alive 5 years after
the disease was detected. A 5-year survival of 50% means that
after 5 years, 50 out of 100 patients are still alive. The other 50
people may have died due to the recurrence of the disease, but
may also well have died from other causes such as a heart
attack
70 66 65 —
Probability of five-year local
control
a (all patients)
This is the probability that the tumour does not recur at the site
that was operated on. If the tumour does recur at that site, it
causes a lot of pain. It may in some instances be possible to
treat it, but in others not. Often the prognosis is uncertain
99 94 89 —
Probability of faecal
incontinence (all patients)
Incontinence in this interview refers to incontinence for stools
and means unintentionally losing stools
20 40 60 80
Probability of sexual
dysfunction (male patients)
You may think of problems with getting an erection (¼erectile
dysfunction) and with ejaculation, or of not being sexually active
at all anymore
30 40 50 60
Probability of sexual
dysfunction (female patients)
Dissatisfaction with sexuality usually results from not being able
to enjoy sexual intercourse anymore because of pain or vaginal
dryness
10 30 50 70
Abbreviation: ACA, Adaptive Conjoint Analysis.
aThe expression ‘probability of local control’ was not used in patients but was explained as ‘probability that the tumour does not
recur’.
Incontinence:  20 out of 100 people 
vs 
Incontinence:  80 out of 100 people
Five-year survival:
Incontinence:
66 out of 100 people
20 out of 100 people
vs 70 out of 100 people 
40 out of 100 people
1 
Not 
important
2
Somewhat
important
3 
Important
4 
Very 
important 
Pairwise comparison between combinations of treatment outcomes
(two-outcome example) 
'All else being equal, which would you prefer?'
Importance of difference between best and worst probability of a treatment outcome
(example)
'All other things being equal, how important is this difference to you?'
1 24567
Strongly 
prefer right
Strongly 
prefer left
Figure 2 Adaptive conjoint analysis questionnaire.
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scould not decide for female patients. In the remaining oncologists,
required benefit from PRT for male vs female patients was
identical for 54 out of 57 (95%, 1 missing value) and 1% higher or
1–2% lower for male patients in other cases. Results were
therefore pooled. On average, minimally desired benefit was
5.0% (95% CI, 4.6–5.4; range 1–10). Most frequently cited (by
N¼30) desired benefit was 5% (Figure 3). Minimally desired
benefit was, respectively, 4.7±1.2, 5.0±0.5, and 5.3±1.8 for
radiation, medical, and surgical oncologists (P¼0.56). Minimally
desired benefit was not correlated with age, time since specialisa-
tion, current workplace, having ever supervised internships or
residencies, or having ever been part of a guideline committee
(data not shown).
For a 5% benefit in local control, there was a trend for
oncologists to prefer PRT more often than patients (79 vs 64%,
P¼0.06). Oncologists preferred PRT significantly more often than
non-irradiated patients (79 vs 42%, Po0.001) and about as often
as irradiated patients (79 vs 83%, P¼0.68).
Relative importance of treatment outcomes
Five (4%) participants conferred the highest value to the worst
outcome probability in one of the outcomes and were excluded
from further analyses. Incontinence was the most important
treatment outcome for 29 (47%) patients and 24 (41%) oncologists,
followed by local control for 21 (34%) patients and 20 (34%)
oncologists, survival for 7 (11%) patients and 12 (20%)
oncologists, and sexual dysfunction for 5 (8%) patients and for 3
(5%) oncologists.
Figure 4 shows mean, standard deviation, and range of relative
treatment outcome importance. Relative importance did not differ
between male and female patients, irradiated and non-irradiated
patients, or between those with and without a stoma. An effect of
the experience of the side effects of treatment on the relative
importance of those side effects was not seen either. No differences
were seen between patients who did and who did not suffer from
incontinence with respect to the importance attached to incon-
tinence, and no differences were seen for sexual dysfunction
between patients who did and who did not indicate sexual
problems.
Mean importance was significantly different between specialties
for local control (P¼0.01), survival (P¼0.02), and sexual
dysfunction (P¼0.024). Radiotherapists considered local control
more important than medical oncologists (35±9 vs 24±8,
P¼0.02) and surgeons (28±11, P¼0.04). Surgeons considered
sexual dysfunction more important than radiotherapists (20±9 vs
14±5, P¼0.02). There was a trend (P¼0.05) for medical
oncologists to consider survival more important than surgeons
(28±9 vs 17±12). Relative importance of treatment outcomes for
Table 2 Participants’ background details
Participants N (%)
Patients (N¼66)
Mean age, years±s.d. (range) 64±9.2 (41–84)
Mean time since surgery, years±s.d. (range) 8±1.0 (6–10)
Treatment
Surgery 31 (47)
PRT+surgery 35 (53)
Permanent stoma
Yes 25 (38)
No 41 (62)
Incontinence (non-stoma patients)
Never 23 (56)
Sometimes 17 (41)
Often 1 (2)
Always 0
Oncologists (N¼60)
Mean age, years±s.d. (range) 48±7.3 (35–62)
Mean time since specialisation, years±s.d. (range) 13±8.1 (1–31)
Current institution
Academic 14 (23)
Non-academic 46 (77)
Supervisor (ever)
Yes 9 (15)
No 50 (85)
Member of a guideline committee (ever)
Yes 13 (22)
No 47 (78)
Adherence to 2001 guideline
a
Overall yes 53 (90)
Yes, except for high tumours 2 (3)
No, not in general 4 (7)
Numbers do not add up to 60 in oncologists due to missing data.
aReported rectal
cancer treatment management within the oncologist’s institution.
0
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Figure 3 Cumulative proportion of oncologists (N¼58) and patients (N¼66) preferring PRT according to minimum percentage of benefit in local
control. Numbers of patients do not add up to 100% because of those never preferring PRT.
Rectal cancer patients’ and oncologists’ treatment preferences
AH Pieterse et al
721
British Journal of Cancer (2007) 97(6), 717–724 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
soncologists did not differ according to patient gender or
oncologists’ background characteristics (data not shown), except
that clinicians who had supervised tended to consider local control
as more important than clinicians who had not (36±9 vs 29±10
P¼0.05).
Mean relative importance of probability of sexual dysfunction
was significantly higher for patients than for oncologists (21±8 vs
17±8, P¼0.02).
DISCUSSION
The Dutch TME trial showed that short-course PRT improves local
control in resectable rectal cancer patients, with no survival gain
(Peeters et al, 2007). Given the high rates of local control with
surgery alone (Peeters et al, 2007), 90–95% of patients are
unnecessarily treated with PRT. Radiotherapy has been shown to
induce major side effects, including faecal incontinence (Marijnen
et al, 2005; Peeters et al, 2005), sexual dysfunction (Marijnen et al,
2005), small bowel obstruction (Birgisson et al, 2005a), and
development of secondary tumours (Birgisson et al, 2005b). The
awareness of side effects often leads to discussions in multi-
disciplinary oncology meetings about the necessity of PRT for
certain patients. One would expect that a small probability of
benefit and large probabilities of side effects would call for the
input of the patient in the process of decision-making. However,
in the Netherlands, these probabilities are often not explicitly
discussed with the patient, and the decision about PRT is even less
frequently left to the patient. We therefore performed this study to
evaluate patients’ and oncologists’ preferences for preoperative
treatment. Investigating how new rectal cancer patients value the
tradeoff between local control and side effects is difficult in the
Netherlands, where neoadjuvant radiation is the standard treat-
ment. We therefore recruited disease-free rectal cancer patients
treated in the TME trial as an alternative, enabling us to assess
views from patients with and without experience with PRT and
side effects.
The TTM methodology showed that patients preferred to be
irradiated when the mean gain in local control was about 5%. The
range was considerable (0–11%) though, highlighting the need for
a discussion of the pros and cons of PRT with every patient with
resectable rectal cancer.
One of the drawbacks of this study is the use of already treated
patients, who have been disease-free for over 5 years. To these
patients, 5-year survival and 5-year local control rates will have
another connotation than to recently diagnosed patients. Since
oncologists in the Netherlands are reluctant to discuss these
absolute rates explicitly with patients, we deemed it impossible to
use the methods with recently diagnosed patients. We were aware
that our retrospective interviews would incorporate the biases
generally seen in the literature, but by asking all types of patients,
both with and without treatment experience, and with and without
symptoms, we wished to obtain an impression of all possible
attitudes towards the tradeoffs involved. Patients have been shown
to have a strong preference for the therapy they have undergone
(Yellen et al, 1994; McQuellon et al, 1995; Stiggelbout et al, 1996;
Lindley et al, 1998; Jansen et al, 2001), possibly embracing it
psychologically as the best possible for them. Indeed, patients in
this study who underwent PRT desired a lower benefit from
irradiation than non-irradiated patients. A significant minority
preferred PRT even if the treatment was non-beneficial and
harmful, in accordance with studies on adjuvant chemotherapy
(Ravdin et al, 1998; Jansen et al, 2001) and adjuvant radiotherapy
(Palda et al, 1997). Again, this preference may result from
cognitive justification, but may also be grounded in expecting or
having experienced non-clinical benefits, including a sense of
control over one’s situation (Levine et al, 1988), persistent belief in
treatment benefit (Palda et al, 1997), or avoiding negative feelings
including regret over having refused treatment (Palda et al, 1997).
One should take this into account when judging the absolute
benefit that our patients required from treatment. The number for
newly diagnosed patients will likely lie in between the means of our
two patient groups.
On the basis of the frequent discussions in multidisciplinary
team meetings, we hypothesised that required benefit from PRT
would differ between specialties. However, our results showed that
most oncologists, regardless of specialty, prefer PRT when the gain
in local control is 5%. This is a generally accepted benefit in Dutch
oncologists regarding adjuvant treatment in general (Bontenbal
et al, 2000). The fact that the TME trial showed 5% benefit at
0
10
20
30
40
50
60
70
Local control
Pt Clin
Survival
Pt Clin
Sexual dysfunction
Pt Clin
Incontinence
Pt Clin
30±12 27±9 30±10 21±10 22±11 21±8 17±8  31±11 M±s.d.
Figure 4 Individual importance scores (range 0–100) of treatment outcomes in patients and clinicians. M¼mean; s.d.¼standard deviation; Pt¼patient;
Clin¼clinician. One oncologist and four patients were excluded from the analyses because they valued the worst probability of one of the treatment
outcomes highest compared to the other outcome probabilities of that outcome.
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so rarely presented to the patient as a choice or a decision to be
made. Nevertheless, the range in local control we established for
patients to prefer PRT demonstrates that lack of choice may not be
justified.
Regarding relative preferences for treatment outcomes, findings
were highly comparable between patients and oncologists. First, in
both groups about 40% of participants considered faecal incon-
tinence as the major drawback of rectal cancer treatment. The
relative importance of tumour control, survival, and sexual
functioning was also similar in both groups. Second, there was
large between-subject variation in the importance of local control,
survival, incontinence, and sexual functioning in determining
participants’ preferences for outcome states. This indicates that
both individual patients and individual oncologists greatly vary in
their perception of how tumour control, survival, and quality of
life should be weighed in deciding upon the most preferable
treatment.
The relative importance of the various outcomes of treatment
was similar for irradiated and non-irradiated patients. This finding
from ACA is in contrast to preferences as assessed using the TTM.
It may be explained by the different cognitive processes invoked by
the two tasks. In contrast to the TTM, the ACA does not identify
treatment modality. Cognitive justification of a previous treatment
experience, seen in the TTM, will therefore not strongly influence
preferences.
ACA explicitly asks to evaluate tradeoffs between benefits and
side effects, a task that is highly relevant to treatment decision-
making in oncology. This method, which is novel to the field of
oncology, is therefore promising, and indeed the large majority
of our oncologists felt this to be the case (55% definitely, 27%
possibly). Analysis of data we are currently gathering among
patients (N¼28) who have been treated more recently
(M¼1.8±1.1 years ago; range 0.4–5.6) suggests that for them
incontinence, tumour control, survival, and sexual dysfunction
determined in that order preferences for treatment outcome, as
was the case for the patients in this study. Also, how important
these outcomes were rated on average did not significantly differ
from this patient group. These findings suggest that for disease-
free patients who are still within 5 years of surgery, local control is
not more important and quality of life not less important than to
patients who have survived disease-free beyond 5 year.
Differences in the importance of the various treatment outcomes
were seen between specialties. Tumour control was more
important to radiation than to other oncologists, possibly because
that is the benefit that can be gained from the treatment they offer.
This finding is in accord with results showing that specialists tend
to believe in the therapy they deliver, as was found for urologists
and radiotherapists in the treatment of localised prostate cancer
(Fowler et al, 2000), and for medical oncologists in adjuvant
chemotherapy treatment for breast cancer (Stiggelbout et al, 2000).
Sexual dysfunction was somewhat more important to surgical than
to radiation oncologists. Additional analyses suggest that relative
importance of sexual dysfunction cannot be explained by the
difference in gender distribution between specialties, since the
relative importance did not differ overall between male and
female oncologists (data not shown). The small number of
female oncologists, however, prevents us from drawing strong
conclusions.
Sexual functioning was equally important to male and female
patients, and more strongly determined patients’ than oncologists’
preferences. This result suggests that the harmful effect of
treatment on this aspect of patients’ lives deserves attention, and
possibly to a larger extent than oncologists may think.
In conclusion, treatment preferences differ between individual
patients, individual oncologists, and oncologists from different
specialties treating the same patient. This inter-individual
variability, coupled with the prospect of a long life expectancy
after surgery, indicates that oncologists should provide patients
with comprehensive information about benefits and side effects of
neoadjuvant radiation, and elicit patients’ outcome preferences in
the process of treatment decision-making.
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